Viola Schweinsberg

Feb 21, 2025 | nature.com | Maximilian Merz |David Fandrei |Eva Heger |Viola Schweinsberg |Uwe Platzbecker |Michael Hallek | +3 more

AbstractChimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. Nine months after CAR T therapy, he developed a symptomatic leukemic peripheral T cell lymphoma with cutaneous and intestinal involvement.